Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present TherapeuticsMD, Inc. (NASDAQ: TXMD).

Full DD Report for TXMD

You must become a subscriber to view this report.


Recent News from (NASDAQ: TXMD)

TherapeuticsMD Announces Commercial Availability of Imvexxy(TM) 4 mcg
Imvexxy 4 mcg dose now commercially available in the United States TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States. ...
Source: Business Wire
Date: September, 13 2018 07:00
High Value Cannabis and Biotech Stocks
HENDERSON, NV / ACCESSWIRE / September 11, 2018 / A very interesting biotechnology company ENDV (Endonovo Therapeutics, Inc.), has an FDA cleared product, and is flying under the radar. ENDV has been on an uptrend over the last couple weeks. ENDV may start receiving increased attention from ...
Source: ACCESSWIRE IA
Date: September, 11 2018 10:30
Buy Urban Outfitters On Weakness - Cramer's Lightning Round (9/7/18)
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, September 7 . Bullish Calls Urban Outfitters (URBN): The stock has doubled, but it's an incredibly well-run company. Buy more when it comes down. CenturyLink (CTL): It's a value stock, and Cramer ...
Source: SeekingAlpha
Date: September, 10 2018 06:22

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-146.356.376.446.251,564,534
2017-03-106.836.736.836.62112,146
2017-03-096.696.756.866.641,437,408
2017-03-086.356.696.776.351,322,652
2017-03-076.426.456.606.29461,779,618

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10396,958666,57559.5519Short
2018-12-07381,117553,20968.8920Short
2018-12-06941,3611,192,09778.9668Short
2018-12-04421,848564,04774.7895Short
2018-12-03364,126659,73555.1928Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TXMD.


About TherapeuticsMD, Inc. (NASDAQ: TXMD)

Logo for TherapeuticsMD, Inc. (NASDAQ: TXMD)

VitaMed is a specialty pharmaceutical company that has developed a patent pending technology and business methodology to market both over the counter OTC and prescription versions of nutritional supplements, drugs, medical foods and other medical products directly to consumers with the recommendation of their physician. VitaMed s business model creates unique value propositions for patients, physician/providers and insurance payors by eliminating much of the inefficiencies associated with the traditional sales, marketing and distribution models. VitaMed offers superior quality products for a lower overall cost to patients and payors while increasing efficiencies for physicians. VitaMed s technology allows it to collect and analyze data from various sources to improve patient compliance and education, facilitate product development and provide immediate feedback on effectiveness of therapies. The result is increased efficiency and communication between the patient, physician/provider and insurance payor, ultimately creating improved outcomes for all. This combination of efficient distribution and technology provides measurable customer benefits differentiates VitaMed from existing competitors in the market.

 

Contact Information

 

 

Current Management

  • Robert Finizio / CEO
  • John C.K. Milligan, IV / President, Corporate Secretary
  • Daniel A. Cartwright / CFO, VP, Fin., Treasurer
  • Mitchell Krassan / Chief Strategy Officer
  • Robert Finizio / Chairman
  • Brian Bernick /
  • Cooper Collins /
  • Samuel A. Greco /
  • John C.K. Milligan, IV /
  • Robert V. LaPenta /
  • Nicholas Segal /
  • Tommy G. Thompson /

Current Share Structure

  • Market Cap: $1,363,568,743 - 05/18/2018
  • Authorized: 250,000,000 - 10/23/2011
  • Issue and Outstanding: 216,439,483 - 02/20/2018
  • Float: 25,550,701 - 10/15/2012

 


Recent Filings from (NASDAQ: TXMD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 21 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: August, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 03 2018
Prospectus filed under Rule 424(b)(2)
Filing Type: 424B2Filing Source: edgar
Filing Date: August, 02 2018
Prospectus filed under Rule 424(b)(2)
Filing Type: 424B2Filing Source: edgar
Filing Date: August, 02 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: July, 31 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: July, 31 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: July, 31 2018

 

 


Daily Technical Chart for (NASDAQ: TXMD)

Daily Technical Chart for (NASDAQ: TXMD)


Stay tuned for daily updates and more on (NASDAQ: TXMD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: TXMD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TXMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TXMD and does not buy, sell, or trade any shares of TXMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/